0001209191-24-000369.txt : 20240103 0001209191-24-000369.hdr.sgml : 20240103 20240103162131 ACCESSION NUMBER: 0001209191-24-000369 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231231 FILED AS OF DATE: 20240103 DATE AS OF CHANGE: 20240103 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Forman Mark S CENTRAL INDEX KEY: 0001922353 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39231 FILM NUMBER: 24506793 MAIL ADDRESS: STREET 1: C/O PASSAGE BIO, INC. STREET 2: 2005 MARKET STREET, 39TH FLOOR CITY: PHILADELPHIA STATE: PA ZIP: 19103 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Passage BIO, Inc. CENTRAL INDEX KEY: 0001787297 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 822729751 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE COMMERCE SQUARE STREET 2: 2005 MARKET STREET, 39TH FLOOR CITY: PHILADELPHIA STATE: PA ZIP: 19103 BUSINESS PHONE: 2678660312 MAIL ADDRESS: STREET 1: ONE COMMERCE SQUARE STREET 2: 2005 MARKET STREET, 39TH FLOOR CITY: PHILADELPHIA STATE: PA ZIP: 19103 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2023-12-31 0 0001787297 Passage BIO, Inc. PASG 0001922353 Forman Mark S ONE COMMERCE SQUARE 2005 MARKET STREET, 39TH FLOOR PHILADELPHIA PA 19103 0 1 0 0 Chief Medical Officer 0 Common Stock 2023-12-31 4 M 0 50000 A 61082 D Common Stock 2024-01-02 4 S 0 15813 0.91 D 45269 D Restricted Stock Unit 2023-12-31 4 M 0 50000 0.00 D Common Stock 50000 0 D Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. Includes 3,082 shares acquired on May 13, 2022, 4,000 shares acquired on May 15, 2023, and 4,000 shares acquired on November 15, 2023 under the 2020 Employee Stock Purchase Plan. The sale reported on this Form 4 represents an Issuer mandated sale by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs; it does not represent a discretionary trade by the Reporting Person. Pursuant to the Issuer's equity incentive plan, an award recipient's tax withholding obligations must be funded by a "sell to cover" transaction. Each RSU represents a contingent right to receive one share of Issuer's common stock. 100% of the total restricted stock units vested on December 31, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date. /s/ Edgar Cale, Attorney-in-Fact 2024-01-03